Table 2—

Serum lipid levels and blood pressure at baseline and after 52 weeks, and changes from baseline to end of treatment (ITT, LOCF)

PlaceboOrlistatP
n254250
Total cholesterol (mmol/l)
 Baseline5.40 ± 0.065.40 ± 0.06
 Week 525.46 ± 0.075.13 ± 0.06
 Change (%)2.6 ± 1.0−4.1 ± 0.9<0.0001
LDL cholesterol (mmol/l)
 Baseline3.23 ± 0.063.14 ± 0.06
 Week 523.18 ± 0.072.89 ± 0.06
 Change (%)3.9 ± 2.7−2.8 ± 2.30.044
HDL cholesterol (mmol/l)
 Baseline0.98 ± 0.020.98 ± 0.02
 Week 521.08 ± 0.021.07 ± 0.02
 Change (%)13.8 ± 1.4513.0 ± 1.520.821
LDL/HDL ratio
 Baseline3.51 ± 0.093.43 ± 0.09
 Week 523.07 ± 0.082.86 ± 0.07
 Change−0.46 ± 0.08−0.60 ± 0.070.027
Triglycerides (mmol/l)
 Baseline2.63 ± 0.092.81 ± 0.11
 Week 522.66 ± 0.132.56 ± 0.11
 Change (%)9.0 ± 3.6−0.8 ± 2.760.503
Systolic blood pressure (mmHg)
 Baseline132.1 ± 0.9132.7 ± 0.9
 Week 52131.8 ± 0.9130.6 ± 0.9
 Change (mmHg)−0.4 ± 0.9−2.1 ± 0.80.017
  • Data are means ± SE.